Syros Pharmaceuticals Inc (NASDAQ: SYRS) Stock: Will It Keep Climbing Higher?

In today’s recent session, 0.96 million shares of the Syros Pharmaceuticals Inc (NASDAQ:SYRS) have been traded, and its beta is 1.29. Most recently the company’s share price was $0.25, and it changed around $0.01 or 5.12% from the last close, which brings the market valuation of the company to $6.87M. SYRS at last check was trading at a discount to its 52-week high of $8.17, offering almost -3168.0% off that amount. The share price’s 52-week low was $0.18, which indicates that the recent value has risen by an impressive 28.0% since then. We note from Syros Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 3.32 million shares, with the 3-month average coming to 8.20 million.

Syros Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.50. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 4 recommended SYRS as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Syros Pharmaceuticals Inc is expected to report earnings per share of -0.71 for the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Syros Pharmaceuticals Inc (NASDAQ:SYRS) trade information

Instantly SYRS has been showing a green trend so far today with a performance of 5.12% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.2657 on recent trading dayincreased the stock’s daily price by 5.91%. The company’s shares are currently down -96.76% year-to-date, but still down -1.83% over the last five days. On the other hand, Syros Pharmaceuticals Inc (NASDAQ:SYRS) is -90.14% down in the 30-day period. We can see from the shorts that 4.77 million shares have been sold at a short interest cover period of 1.38 day(s).

The consensus price target as assigned by Wall Street analysts is $10, which translates to bulls needing to increase their stock price by 97.5% from its current value. Analyst projections state that SYRS is forecast to be at a low of $5 and a high of $15.

Syros Pharmaceuticals Inc (SYRS) estimates and forecasts

Syros Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -95.07 percent over the past six months and at a 65.53% annual growth rate that is well above the industry average of 17.10%. The year-over-year growth rate is expected to be -95.47%, down from the previous year.

Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 450k in revenue for the current quarter. Analysts predict that the company’s current quarter sales will jump, forecast at 16.58%. Forecasts for the next quarter put sales growth at 0.00%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 21.16%.

SYRS Dividends

Syros Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in January.

Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 0.74% of Syros Pharmaceuticals Inc shares, and 75.59% of them are in the hands of institutional investors. The stock currently has a share float of 76.15%.

Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Sep 30, 2024. The former held 654.18 shares worth $0.17 million, making up 2.44% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 257.63 shares worth around $65361.0, which represents about 0.96% of the total shares outstanding.